Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: A multicentre, open-label, phase IV study

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Lugaresi, Alessandra ^a   Florio, Ciro ^b   Brescia Morra, Vincenzo ^c   Cottone, Salvatore ^d   Bellantonio, Paolo ^e   Clerico, Marinella ^f   Centonze, Diego ^g   Uccelli, Antonio ^h   di Ioia, Maria ^a   De Luca, Giovanna ^a   Marcellusi, Andrea ^g   Paolillo, Andrea ⁱ  

^a UNIVERSITY OF CHIETI   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello   (Italy)

^e IRCCS NEUROMED   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ Merck Serono SpA   (Italy)

Author keywords

Drug delivery systems; IFN beta; Medication adherence; Relapsing remitting multiple sclerosis; Self administration

Indexed keywords

BETA1A INTERFERON; BETA INTERFERON; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PHYSICAL EXAMINATION; QUESTIONNAIRE; SCORING SYSTEM; SELF INJECTION; SIDE EFFECT; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DISABILITY; DRUG DELIVERY SYSTEM; DRUG SELF ADMINISTRATION; FOLLOW UP; MIDDLE AGED; PAIN ASSESSMENT; PSYCHOLOGICAL ASPECT; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; DISABILITY EVALUATION; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PAIN MEASUREMENT; PATIENT COMPLIANCE; SELF ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857679291     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-7     Document Type: Article

References (33)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231. 10.1016/S0140-6736(02)08220-X, 11955556.
2. Lesaux J, Jadback G, Harraghy CE. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis. J Neurosci Nurs 1999, 31:174-179. 10.1097/01376517-199906000-00006, 10846648.
3. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003, 61:551-554.
4. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008, 10:225. 2580090, 19008986.
5. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009, 256:568-576. 10.1007/s00415-009-0096-y, 19444532.
6. Al-Sabbagh A, Bennet R, Kozma C, Dickson M, Meletiche D. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008, 255(Suppl 2):S79.
7. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010, 30:89-100. 10.2165/11533330-000000000-00000, 20067327.
8. Singer B, Lucas S, Kresa-Reahl K, Perrin Ross A, Blake P. Optimizing adherence to multiple sclerosis therapies. Int J MS Care 2008, 10(Suppl):113.
9. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006, 38:167-171. 10.1097/01376517-200606000-00005, 16817668.
10. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001, 23:125-132. 10.1207/S15324796ABM2302_7, 11394554.
11. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?. Expert Opin Drug Deliv 2009, 6:995-1002. 10.1517/17425240903134769, 19637982.
12. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006, 245:41-46. 10.1016/j.jns.2005.08.019, 16643953.
13. Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006, 113:156-162. 10.1111/j.1600-0404.2005.00568.x, 16441244.
14. Devonshire V, Arbizu T, Borre B, Lang M, Lugaresi A, Singer B, Verdun di Cantogno E, Cornelisse P. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol 2010, 10:28. 10.1186/1471-2377-10-28, 2877661, 20433746.
15. Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Clin Neuropharmacol 2008, 31:167-172. 10.1097/wnf.0b013e3181571a8e, 18520983.
16. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J, . Rebiject™ Study Group A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005, 11:585-591. 10.1191/1352458505ms1197oa, 16193898, Rebiject™ Study Group.
17. Pozzilli C, Schweikert B, Ecari U, Oentrich W. Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis-Results of the BetaPlus observational cohort study. J Neurol Sci 2011, 307:120-126. 10.1016/j.jns.2011.04.026, 21636099.
18. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria'. Ann Neurol 2005, 58:840-846. 10.1002/ana.20703, 16283615.
19. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15:565-574. 10.1002/pds.1230, 16514590.
20. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
21. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011, 5:73-84. 3058604, 21423591.
22. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010, 26:663-674. 10.1185/03007990903554257, 20070144.
23. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006, 67:944-953. 10.1212/01.wnl.0000237994.95410.ce, 17000959.
24. PRISMS Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504. 10.1016/S0140-6736(98)03334-0, 9820297, PRISMS Study Group.
25. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001, 56:1628-1636. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group.
26. Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler 2010, 16:112-120. 10.1177/1352458509351897, 19995835.
27. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ, Nos C, Montalban X. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005, 11:306-309. 10.1191/1352458505ms1173oa, 15957512.
28. Singer B, Wray S, Miller T, Cascione M, Gupta A, Pardo G, Watsky E, Mercer B, Dangond F. Final results from a 12-week, phase IIIb trial to evaluate an electronic autoinjector in patients with relapsing multiple sclerosis. Neurology 2011, 76(Suppl 4):A321-A322.
29. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995, 45:1268-1276.
30. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, . EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study. Arch Neurol 2005, 62:785-792. 10.1001/archneur.62.5.785, 15883267, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group.
31. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005, 239:67-74. 10.1016/j.jns.2005.08.003, 16169561.
32. Reess J, Haas J, Gabriel K, Fuhlrott A, Fiola M. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Mult Scler 2002, 8:15-18.
33. Ng JL, Morgan DJ, Loh NK, Gan SK, Coleman PL, Ong GS, Prentice D. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust 2011, 194:313-316.